Dyne Therapeutics (NASDAQ:DYN) Receives Buy Rating from Chardan Capital
Chardan Capital reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a report published on Friday,Benzinga reports. Chardan Capital currently has a $50.00 target price on the stock. DYN has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $46.00 target price […]
Chardan Capital reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a report published on Friday,Benzinga reports. Chardan Capital currently has a $50.00 target price on the stock. DYN has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $46.00 target price […]
